피하 약물전달 기기 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Subcutaneous Drug Delivery Devices Market Size, Share & Trends Analysis Report By Product (Prefilled Syringes, Pen Injectors), By Distribution Channel (Retail Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,194,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,571,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,325,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

피하 약물전달 기기 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 피하 약물전달 기기 시장 규모는 2030년까지 518억 달러에 달할 것으로 예상되며, 2025-2030년까지 연평균 7.6%의 성장률을 기록할 것으로 예측됩니다.

만성질환의 유병률 증가와 질병 증상 완화를 위한 정기적인 약물 투여로 인해 가정용 약물 투여 장치에 대한 수요가 증가하고 있습니다. 미국 질병예방통제센터(CDC)에 따르면, 2018년 미국에서는 약 5,440만 명(22.7%)의 성인이 관절염, 섬유근육통, 통풍, 루푸스 등을 앓고 있습니다.

또한, 다량 투여 또는 투여 기간 연장이 필요한 환자의 생명을 위협하는 질병을 치료하기 위한 생물학적 제제의 승인 건수가 증가하면서 피하 약물전달 기기에 대한 수요가 증가하고 있습니다. 영국 인포마(Informa)가 2019년 2월 발표한 조사에 따르면, 임상시험 파이프라인에 있는 의약품의 총 수는 비경구 투여가 2018년 53.0%에서 2019년 55.0%로 증가했으며, 경구용 의약품 제제는 2018년 33.0%에서 2019년 31.0%로 전반적으로 감소했습니다.

피하 약물전달 기기 시장 보고서 하이라이트

• 노년층의 만성질환 유병률 증가와 높은 가처분 소득으로 인해 북미가 2024년 가장 큰 매출 점유율을 차지했습니다.
• 제품별로는 다회 투여가 용이하고 가격이 저렴한 펜형 주사기가 예측 기간 동안 가장 높은 CAGR을 기록할 것으로 예상됩니다.
• 유통 채널별로는 소매 약국 부문이 가장 큰 시장 점유율을 차지하고 있는데, 여기에는 대형 약국 체인이 포함되며 새로운 약물전달 장비에 대한 매력적인 계획과 할인이 있기 때문입니다.
• 시장 진입 기업들은 세계 시장에서 환자 수요 증가에 대응하기 위해 전략적 제휴, 제품 혁신 등 여러 가지 전략을 채택하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 피하 약물전달 기기 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 피하 약물전달 기기 시장 분석 툴
  • 산업 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 피하 약물전달 기기 시장 : 제품별, 추정·동향 분석

• 부문 대시보드
• 피하 약물전달 기기 시장 : 제품 변동 분석
• 피하 약물전달 기기 시장 : 제품별 전망
• 2018-2030년 시장 규모와 예측과 동향 분석
• 프리필드 시린지
• 펜형 주사기
• 오토인젝터
• 웨어러블 인젝터
• 무바늘 주사기

제5장 피하 약물전달 기기 시장 : 유통 채널별, 추정·동향 분석

• 부문 대시보드
• 피하 약물전달 기기 시장 : 유통 채널 변동 분석
• 피하 약물전달 기기 시장 : 유통 채널별 전망
• 2018-2030년 시장 규모와 예측과 동향 분석
• 병원 약국
• 소매 약국
• 온라인 약국

제6장 피하 약물전달 기기 시장 : 지역별, 추정·동향 분석

• 지역 대시보드
• 피하 약물전달 기기 시장 : 지역별 변동 분석
• 피하 약물전달 기기 시장 : 유통 채널과 최종 용도별 지역 추정·동향 분석
• 2018-2030년 시장 규모와 예측과 동향 분석
• 북미
  • 미국
  • 캐나다
  • 멕시코
  • 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 상황

• 시장 진출 기업 분류
• 주요 기업 개요
  • Gerresheimer AG
  • Medtronic Plc
  • Ypsomed AG
  • Elcam Medical Group
  • Novo Nordisk
  • Insulet Corporation
  • Becton, Dickinson and Company
  • West Pharmaceutical Services, Inc.
  • PharmaJet
  • Unilife Corporation
  • Inolife Sciences

ksm

영문 목차

영문목차

Subcutaneous Drug Delivery Devices Market Growth & Trends:

The global subcutaneous drug delivery devices market size is expected to reach USD 51.8 billion by 2030, registering to grow at a CAGR of 7.6% from 2025 to 2030 according to a new report by Grand View Research, Inc. The increasing prevalence of chronic conditions combined with regular medicine administration to relive disease symptoms has enhanced the demand for in-home drug administration devices. As per the Centers for Disease Control and Prevention (CDC), in 2018, about 54.4 million adults, amounting to 22.7% suffered from arthritis, fibromyalgia, gout, or lupus in the U.S. The CDC further stated that by 2040, an estimated 78.0 million adults accounting for 26.0% will be diagnosed with arthritis.

In addition, a rising number of biologic medicine approvals for the treatment of life-threatening conditions in patients requiring large dose volumes or extended delivery periods accelerate the demand for subcutaneous drug delivery devices. According to the study published by Informa U.K., in February 2019, the total number of medicines in the clinical trial pipeline increased from 53.0% in 2018 to 55.0% in 2019 for parenteral administrations, with an overall decrease in oral medicine formulations from 33.0% in 2018 to 31.0% in 2019.

Subcutaneous Drug Delivery Devices Market Report Highlights:

• North America accounted for the largest revenue share in 2024 owing to the rising prevalence of chronic diseases in the geriatric population and high disposable income
• By product, injection pen is expected to register the highest CAGR during the forecast period owing to ease in providing multi-dose medicine and affordability
• By distribution channel, the retail pharmacies segment accounted for the largest market share as they include large pharmacy chains and attractive schemes and discounts for the novel medicine delivery devices
• Market players are adopting several strategies such as strategic collaborations and product innovations to cater to the increasing patient demand in the global market.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Distribution Channel
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Distribution Channel outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Subcutaneous Drug Delivery Devices Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising prevalence of chronic diseases
    • 3.2.1.2. Increasing production of biologics
    • 3.2.1.3. Increasing product innovations and approvals
    • 3.2.1.4. Increasing focus on self-administration, prevention of needlestick injuries and dosing errors
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of advanced delivery systems
    • 3.2.2.2. Lack of awareness in developing countries
• 3.3. Subcutaneous Drug Delivery Devices Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Subcutaneous Drug Delivery Devices Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Subcutaneous Drug Delivery Devices Market: Product Movement Analysis
• 4.3. Subcutaneous Drug Delivery Devices Market by Product Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Prefilled Syringes
  • 4.5.1. Prefilled Syringes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Pen Injectors
  • 4.6.1. Pen Injectors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Auto Injectors
  • 4.7.1. Auto Injectors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Wearable Injectors
  • 4.8.1. Wearable Injectors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.9. Needle-free Injectors
  • 4.9.1. Needle-free Injectors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Subcutaneous Drug Delivery Devices Market: Distribution Channel Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Subcutaneous Drug Delivery Devices Market: Distribution Channel Movement Analysis
• 5.3. Subcutaneous Drug Delivery Devices Market by Distribution Channel Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Hospital Pharmacies
  • 5.5.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Retail Pharmacies
  • 5.6.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Online Pharmacies
  • 5.7.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Subcutaneous Drug Delivery Devices Market: Regional Estimates & Trend Analysis

• 6.1. Regional Dashboard
• 6.2. Regional Subcutaneous Drug Delivery Devices Market Movement Analysis
• 6.3. Subcutaneous Drug Delivery Devices Market: Regional Estimates & Trend Analysis by Distribution Channel & End-use
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. North America
  • 6.5.1. North America Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. U.S.
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Competitive Scenario
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement scenario
    • 6.5.2.5. U.S. Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Canada
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Competitive Scenario
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement scenario
    • 6.5.3.5. Canada Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. Mexico
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Competitive Scenario
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. Reimbursement scenario
    • 6.5.4.5. Mexico Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Europe
  • 6.5.6. Europe Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. UK
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Competitive Scenario
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. Reimbursement scenario
    • 6.5.7.5. UK Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Germany
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Competitive Scenario
    • 6.5.8.3. Regulatory Framework
    • 6.5.8.4. Reimbursement scenario
    • 6.5.8.5. Germany Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.9. France
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Competitive Scenario
    • 6.5.9.3. Regulatory Framework
    • 6.5.9.4. Reimbursement scenario
    • 6.5.9.5. France Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.10. Italy
    • 6.5.10.1. Key Country Dynamics
    • 6.5.10.2. Competitive Scenario
    • 6.5.10.3. Regulatory Framework
    • 6.5.10.4. Reimbursement scenario
    • 6.5.10.5. Italy Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.11. Spain
    • 6.5.11.1. Key Country Dynamics
    • 6.5.11.2. Competitive Scenario
    • 6.5.11.3. Regulatory Framework
    • 6.5.11.4. Reimbursement scenario
    • 6.5.11.5. Spain Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.12. Denmark
    • 6.5.12.1. Key Country Dynamics
    • 6.5.12.2. Competitive Scenario
    • 6.5.12.3. Regulatory Framework
    • 6.5.12.4. Reimbursement scenario
    • 6.5.12.5. Denmark Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.13. Sweden
    • 6.5.13.1. Key Country Dynamics
    • 6.5.13.2. Competitive Scenario
    • 6.5.13.3. Regulatory Framework
    • 6.5.13.4. Reimbursement scenario
    • 6.5.13.5. Sweden Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.14. Norway
    • 6.5.14.1. Key Country Dynamics
    • 6.5.14.2. Competitive Scenario
    • 6.5.14.3. Regulatory Framework
    • 6.5.14.4. Reimbursement scenario
    • 6.5.14.5. Norway Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Competitive Scenario
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement scenario
    • 6.6.2.5. Japan Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Competitive Scenario
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement scenario
    • 6.6.3.5. China Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Competitive Scenario
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Reimbursement scenario
    • 6.6.4.5. India Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. South Korea
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Competitive Scenario
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Reimbursement scenario
    • 6.6.5.5. South Korea Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. Australia
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Competitive Scenario
    • 6.6.6.3. Regulatory Framework
    • 6.6.6.4. Reimbursement scenario
    • 6.6.6.5. Australia Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Competitive Scenario
    • 6.6.7.3. Regulatory Framework
    • 6.6.7.4. Reimbursement scenario
    • 6.6.7.5. Thailand Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Competitive Scenario
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Reimbursement scenario
    • 6.7.2.5. Brazil Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Competitive Scenario
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Reimbursement scenario
    • 6.7.3.5. Argentina Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. Middle East & Africa
  • 6.8.1. Middle East & Africa Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Competitive Scenario
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Reimbursement scenario
    • 6.8.2.5. South Africa Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Competitive Scenario
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. Reimbursement scenario
    • 6.8.3.5. Saudi Arabia Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Competitive Scenario
    • 6.8.4.3. Regulatory Framework
    • 6.8.4.4. Reimbursement scenario
    • 6.8.4.5. UAE Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Competitive Scenario
    • 6.8.5.3. Regulatory Framework
    • 6.8.5.4. Reimbursement scenario
    • 6.8.5.5. Kuwait Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Market Participant Categorization
• 7.2. Key Company Profiles
  • 7.2.1. Gerresheimer AG
    • 7.2.1.1. Company overview
    • 7.2.1.2. Financial performance
    • 7.2.1.3. Product benchmarking
    • 7.2.1.4. Strategic initiatives
  • 7.2.2. Medtronic Plc
    • 7.2.2.1. Company overview
    • 7.2.2.2. Financial performance
    • 7.2.2.3. Product benchmarking
    • 7.2.2.4. Strategic initiatives
  • 7.2.3. Ypsomed AG
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Elcam Medical Group
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. Novo Nordisk
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. Insulet Corporation
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. Becton, Dickinson and Company
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. West Pharmaceutical Services, Inc.
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives
  • 7.2.9. PharmaJet
    • 7.2.9.1. Company overview
    • 7.2.9.2. Financial performance
    • 7.2.9.3. Product benchmarking
    • 7.2.9.4. Strategic initiatives
  • 7.2.10. Unilife Corporation
    • 7.2.10.1. Company overview
    • 7.2.10.2. Financial performance
    • 7.2.10.3. Product benchmarking
    • 7.2.10.4. Strategic initiatives
  • 7.2.11. Inolife Sciences
    • 7.2.11.1. Company overview
    • 7.2.11.2. Financial performance
    • 7.2.11.3. Product benchmarking
    • 7.2.11.4. Strategic initiatives

관련자료